Cassady Schiller Wealth Management’s Charles River Laboratories CRL Stock Holding History

Cassady Schiller Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$1.11K	Buy	+6	New	+$1.16K	﹤0.01%	761

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

Cassady Schiller Wealth Management's CRL Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Charles River Laboratories (CRL) in Q4 2024: 6 shares worth $1.11K. The stake represents ﹤0.01% of the portfolio and ranks #761 among its holdings.

635 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

Cassady Schiller Wealth Management held 6 shares of Charles River Laboratories worth $1.11K as of Q4 2024.
Charles River Laboratories was a new Cassady Schiller Wealth Management position in Q4 2024.
Charles River Laboratories made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #761 holding.
635 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.